Ethinylestradiol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ethinylestradiol: Zinc, elevated plasma
One-Sentence Summary
Ethinylestradiol is a synthetic estrogen, originally used for conditions such as acne, postmenopausal osteoporosis and postmenopausal atrophic vaginitis, and it is widely marketed in Australia within combined hormonal contraceptives. The TxGNN model predicts it may be effective for elevated plasma zinc, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Zinc, elevated plasma |
| TxGNN Prediction Score | 0.9963 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (4 of 4 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 4 (valid: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ethinylestradiol is a synthetic estrogen used in combined hormonal products (oral contraceptives and a vaginal ring). Its effects in its established uses are well known, but a mechanistic link to elevated plasma zinc cannot be verified from the data compiled for this report.
One plausible but unconfirmed link is that estrogens are known to alter circulating zinc and copper levels, as seen in oral contraceptive users. This is not supported by the data supplied here, and the direction of effect (raising or lowering zinc) is not established.
Elevated plasma zinc is a laboratory finding rather than a condition that clearly calls for drug treatment. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, so it may not point to a true therapeutic opportunity. The very high score (rank 2283 among predictions) should be interpreted with caution.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
All four entries are products in which ethinylestradiol is combined with a progestogen. No approved indication text is available in the data compiled for this report.
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 15074J | NuvaRing | Vaginal ring containing etonogestrel 11.7 mg with ethinylestradiol 2.7 mg | Not available |
| ARTG 1392G | Trifeme 28 | Pack of 6 tablets (50 µg-30 µg), 5 tablets (75 µg-40 µg), 10 tablets (125 µg-30 µg) and 7 inert tablets | Not available |
| ARTG 14709E | Yaz | Pack of 24 tablets (drospirenone 3 mg with ethinylestradiol 20 µg as betadex clathrate) and 4 inert tablets | Not available |
| ARTG 2774B | Norimin 28 Day | Pack of 21 tablets (500 µg-35 µg) and 7 inert tablets | Not available |
Safety Considerations
Label-derived warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Contraindications suggested by the knowledge graph (not label text): the following conditions are linked to ethinylestradiol by drug-disease contraindication edges and should be verified against the PI:
- Cardiovascular and metabolic: hypertension/hypertensive disorder, congestive heart failure, diabetes mellitus, diabetic ketoacidosis, hyperglycaemia
- Hepatic, biliary and renal: liver disease, gallbladder disease, kidney disease, pyoureter
- Endocrine: hypothyroidism (including myxedema and congenital hypothyroidism), adrenocortical insufficiency/Addison disease, hypercalcaemia (including humoral hypercalcaemia of malignancy)
- Neurological and psychiatric: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder
- Other: porphyria (inherited and other porphyrin metabolism diseases), systemic lupus erythematosus (including paediatric), asthma (intrinsic and allergic), benign prostatic hyperplasia
Drug Interactions: 412 potential interactions were identified. Examples from the first 20 returned include:
- Moderate: acarbose, acetohexamide, albiglutide, alogliptin, chlorpropamide, dulaglutide, empagliflozin, glimepiride, glipizide, glyburide (antidiabetic agents, where glycaemic control may be affected); betamethasone, budesonide, dexamethasone (corticosteroids); doxycycline, amoxicillin, clarithromycin (antibiotics); chenodeoxycholic acid; eliglustat
- Minor: ascorbic acid, cimetidine
The full list should be reviewed before any clinical use.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score, with no clinical trials, no literature and no verified mechanism. Elevated plasma zinc is a laboratory finding rather than a clear treatment target, so the case for repurposing is not established. Safety data from the label is also missing.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) and a mechanistic link to zinc handling
- A literature review of estrogen and oral contraceptive effects on plasma zinc, including direction of effect
- Clarification of whether elevated plasma zinc is a clinically meaningful treatment target
- Product Information warnings and contraindications from the TGA/PBS source, to allow safety screening
- Approved indication text for the Australian entries
- A review of the contraindication list above, which is particularly relevant for any population with elevated zinc, such as those with kidney or liver disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.